<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881878</url>
  </required_header>
  <id_info>
    <org_study_id>2019-01-064</org_study_id>
    <nct_id>NCT03881878</nct_id>
  </id_info>
  <brief_title>TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery</brief_title>
  <official_title>Docetaxel Plus Atezolizumab Plus Herceptin SC and Pertuzumab (TAHP) for Patients With HER2-positive Early Breast Cancer and Subsequent Atezolizumab Plus Herceptin SC and Pertuzumab (AHP) Adjuvant tHerapy After Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was phase IB-II clinical trial that designed to evaluate the efficacy and safety&#xD;
      of docetaxel + atezolizumab + Herceptin sc plus pertuzumab(TAHP) plus adjuvant therapy of&#xD;
      atezolizumab + trastuzumab + pertuzumab(AHP) after surgery in female patients with&#xD;
      HER2-positive early breast cancer.&#xD;
&#xD;
      Adjuvant AHP (atezolizumab + Herceptin SC + pertuzumab) will be continued for remaining 1&#xD;
      year.&#xD;
&#xD;
      For non-p CR patients, they are going to treat with 4 cycles of AC rather than Taxane only&#xD;
      before AHP adjuvant therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A, Neoadjuvant setting); 6 cycles q3weeks, intravenous(IV) administration&#xD;
&#xD;
        -  Docetaxel (75mg/m2, intravenous(IV)) Day(D)1&#xD;
&#xD;
        -  Atezolizumab (1200mg, IV) D1&#xD;
&#xD;
        -  Herceptin sc (600mg subcutaneous(SC))D1&#xD;
&#xD;
        -  Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg(IV))D1&#xD;
&#xD;
      B, Adjuvant setting : 11-12 cycles q3weeks [patients with pCR]&#xD;
&#xD;
        -  Atezolizumab (1200mg, IV)&#xD;
&#xD;
        -  Trastuzumab (600mg, SC)&#xD;
&#xD;
        -  Pertuzumab (420mg, IV) D1&#xD;
&#xD;
      [patients with non-pCR]&#xD;
&#xD;
        -  Doxorubicin(60mg/m2), cyclophosphamide (600mg/m2) D1 X 4cycles 3weeks&#xD;
&#xD;
        -  Atezolizumab (1200mg, IV)&#xD;
&#xD;
        -  Trastuzumab (600mg, SC)&#xD;
&#xD;
        -  Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 27, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>(A, Neoadjuvant setting): TAHP (Docetaxel, Atezolizumab, Trastuzumab sc and Pertuzumab) D1 X 6 cycles q3weeks, intravenous(IV) administration&#xD;
(B, Adjuvant setting) : patients with pCR: AHP(Atezolizumab, Trastuzumab sc and Pertuzumab) D1 X 11-12 cycles q3weeks&#xD;
patients with non-pCR: Doxorubicin plus cyclophosphamide: D1 X 4cycles q3weeks followed by AHP (Atezolizumab, Trastuzumab sc and Pertuzumab) D1 X 11-12 cycles q3weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic CR(pCR) rate of neo-adjuvant chemotherapy</measure>
    <time_frame>Pathologic Clinical response is perforemed after end of cycle 6 (each cycle is 21days).</time_frame>
    <description>pCR rate of neoadjuvant chemotherapy with the patients with HER2+ EBC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event free survival(EFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Event free survival of the patient with pCR vs. non-pCR</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events will be measured by the CTCAE scale, version 5.0</measure>
    <time_frame>1 year</time_frame>
    <description>safety and toxicity</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">67</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>pathologic Complete response</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks&#xD;
Docetaxel (75mg/m2, IV)&#xD;
Atezolizumab (1200mg, IV)&#xD;
Trastuzumab (600mg, SC)&#xD;
Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)&#xD;
(B, Adjuvant setting) : D1 X 11-12 cycles, q3weeks&#xD;
Atezolizumab (1200mg, IV)&#xD;
Trastuzumab (600mg, SC)&#xD;
Pertuzumab (420mg, IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-pathologic Complete response</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks&#xD;
Docetaxel (75mg/m2, IV)&#xD;
Atezolizumab (1200mg, IV)&#xD;
Trastuzumab (600mg, SC)&#xD;
Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)&#xD;
(B, Adjuvant setting) :&#xD;
Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) : D1 X 4cycles q3weeks followed by&#xD;
Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAHP and AHP</intervention_name>
    <description>(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks&#xD;
Docetaxel (75mg/m2, IV)&#xD;
Atezolizumab (1200mg, IV)&#xD;
Tastuzumab (600mg, SC)&#xD;
Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)&#xD;
(B, Adjuvant setting) : patients with pCR:D1 X 11-12 cycles, q3weeks&#xD;
Atezolizumab (1200mg, IV)&#xD;
Trastuzumab (600mg, SC)&#xD;
Pertuzumab (420mg, IV)</description>
    <arm_group_label>pathologic Complete response</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAHP plus AC and AHP</intervention_name>
    <description>(A, Neoadjuvant setting): D1 X 6 cycles, q3weeks&#xD;
Docetaxel (75mg/m2, IV)&#xD;
Atezolizumab (1200mg, IV)&#xD;
Tastuzumab (600mg, SC)&#xD;
Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)&#xD;
(B, Adjuvant setting) : patients with non-pCR&#xD;
Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) D1 X 4cycles q3weeks followed by&#xD;
Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks</description>
    <arm_group_label>non-pathologic Complete response</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is an adult, female ≥ 18 years old at the time of informed consent&#xD;
&#xD;
          2. Patient has histologically confirmed diagnosis of breast cancer&#xD;
&#xD;
          3. Patients with locally advanced breast cancer (T2-3N0-3)&#xD;
&#xD;
          4. Patients with early breast cancer with high-risk (T1cN1)&#xD;
&#xD;
          5. Patients with locally advanced inflammatory breast cancer&#xD;
&#xD;
          6. Patient has HER2-positive breast cancer as 3+ by IHC or in-situ hybridization (ISH)&#xD;
             amplified BC patients&#xD;
&#xD;
          7. ER+ or ER-&#xD;
&#xD;
          8. Agree to informed consent and willing and able to comply with the protocol&#xD;
&#xD;
          9. Available pre-chemotherapy and surgery tissue (except pCR)&#xD;
&#xD;
         10. For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea)&#xD;
             or surgically sterile (absence of ovaries and/or uterus): agreement to remain&#xD;
             abstinent or use single or combined contraceptive methods that result in a failure&#xD;
             rate of &lt; 1% per year during the treatment period and for at least 7 months after the&#xD;
             last dose of study drugs. Abstinence is only acceptable if it is in line with the&#xD;
             preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar,&#xD;
             ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable&#xD;
             methods of contraception.&#xD;
&#xD;
             Examples of contraceptive methods with a failure rate of &lt; 1% per year include tubal&#xD;
             ligation, male sterilization, hormonal implants, established, proper use of combined&#xD;
             oral or injected hormonal contraceptives, and certain intrauterine devices.&#xD;
             Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical&#xD;
             cap) may be combined to achieve a failure rate of &lt; 1% per year. Barrier methods must&#xD;
             always be supplemented with the use of a spermicide.&#xD;
&#xD;
         11. Patient has adequate bone marrow and organ function&#xD;
&#xD;
         12. LVEF ≥55% at baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HER2-negative in surgery sample&#xD;
&#xD;
          2. Tumor size less than 2cm or and N0&#xD;
&#xD;
          3. Patients who have metastatic disease (M1)&#xD;
&#xD;
          4. Patients who are not available tumor tissue&#xD;
&#xD;
          5. Pregnant or lactating or intending to become pregnant during or within 7 months after&#xD;
             the last dose of study treatment&#xD;
&#xD;
          6. Patients who have serious underlying co-morbidities which could cause end-organ&#xD;
             dysfunction&#xD;
&#xD;
          7. Any previous treatment against including chemo, hormonal therapy&#xD;
&#xD;
          8. Administration of a live, attenuated vaccine within 4 weeks before Day 1 or&#xD;
             anticipation that such a live attenuated vaccine will be required during the study&#xD;
&#xD;
          9. History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins&#xD;
&#xD;
         10. Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster&#xD;
             ovary cells or any component of the atezolizumab formulation&#xD;
&#xD;
         11. Patients with prior allogeneic stem cell or solid organ transplantation&#xD;
&#xD;
         12. History of autoimmune disease including, but not limited to, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis&#xD;
             associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's&#xD;
             syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or&#xD;
             glomerulonephritis&#xD;
&#xD;
         13. History of idiopathic pulmonary fibrosis (including bronchiolitis obliterans with&#xD;
             organizing pneumonia) or evidence of active pneumonitis on screening chest computed&#xD;
             tomography scan&#xD;
&#xD;
         14. Known clinically significant liver disease, including active viral, alcoholic, or&#xD;
             other hepatitis, cirrhosis, fatty liver, and inherited liver disease&#xD;
&#xD;
         15. History of HIV infection, active hepatitis B (chronic or acute), or hepatitis C&#xD;
             infection. Patients with past or resolved hepatitis B infection (defined as having a&#xD;
             negative HBsAg test and a positive hepatitis B core antigen [anti-HBc] test) are&#xD;
             eligible.&#xD;
&#xD;
         16. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase&#xD;
             chain reaction assay (PCR) is negative for HCV RNA&#xD;
&#xD;
         17. Active tuberculosis&#xD;
&#xD;
         18. Severe infections within 4 weeks prior to Day 1, including, but not limited to,&#xD;
             hospitalization for complications of infection, bacteremia, or severe pneumonia. Signs&#xD;
             or symptoms of significant infection within 2 weeks prior to Day 1&#xD;
&#xD;
         19. Received oral or IV antibiotics within 2 weeks prior to Cycle 1 Day 1&#xD;
&#xD;
         20. Previous or concomitant malignancy of any other type that could affect compliance with&#xD;
             the protocol or interpretation of results. Patients with curatively treated basal cell&#xD;
             carcinoma of the skin or in situ cervix cancer are generally eligible&#xD;
&#xD;
         21. Congestive heart failure or abnormal LVEF(LVEF is not ≥55% at baseline)&#xD;
&#xD;
         22. Total bili &gt;1.5 ULN (except for Gilbert's syndrome), AST/ALT &gt; 1.5 ULN, ALP &gt; 2.5 ULN&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yeon-hee Park, MD,PhD</last_name>
    <phone>2-3410-3459</phone>
    <phone_ext>82</phone_ext>
    <email>yeonh.park@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>hyunjung shin, CRC</last_name>
    <phone>2-3410-6763</phone>
    <phone_ext>82</phone_ext>
    <email>hjds.shin@samsung.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>March 19, 2019</last_update_submitted>
  <last_update_submitted_qc>March 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Yeon Hee Park</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

